WASHINGTON, Aug.  14, 2026  (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the &#34;Company&#34;), a pharmaceutical company focused on developing new medicines for vector-borne diseases,

SXTP

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

60 Degrees Q2 2026 Results Highlight Limited Revenue Growth and Ongoing Losses

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>WASHINGTON, Aug.  14, 2026  (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) (the &amp;#34;Company&amp;#34;), a pharmaceutical company focused on developing new medicines for vector-borne diseases,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>60 Degrees reported Q2 2026 net product revenue of $208k, up 106% YoY, but net loss was $2.40M ($0.90 per share). Gross profit was $57k; operating expenses rose to $2.33M. The company cites going-concern risk and lack of manufacturing capacity, while pursuing babesiosis trials and ARAKODA sales for malaria prevention.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Q2 2026 net product revenue rose 106% to $208k. Still a net loss.</li><li>Gross profit on product revenues was $57k vs $51k prior year.</li><li>Operating expenses were $2.33M vs $1.86M.</li><li>Going-concern risk cited. No manufacturing capacity.</li><li>Three babesiosis trials underway; ARAKODA approved malaria prevention in 2018.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>60 Degrees Pharmaceuticals, Inc. (SXTP)</strong>: Posted Q2 2026 results; revenue growth but significant losses and liquidity risk; pipeline includes babesiosis trials and ARAKODA product.</li><li><strong>SXTPW Warrants (SXTPW)</strong>: Warrants outstanding; may be affected by stock price moves and dilution considerations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Earnings</h3>
    <p>Category: Earnings. The release summarizes quarterly results, highlighting revenue growth but ongoing losses and liquidity concerns, informing investors about fundamentals and the need for capital and clinical progress.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Q2 revenue growth of 106% to $208k contrasts with ongoing losses.</li><li>Going-concern risk and no manufacturing capacity heighten liquidity concerns.</li><li>Three babesiosis trials and ARAKODA sales shape long-term potential.</li><li>Potential capital needs could lead to dilution and price pressure.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Quarter ended June 30, 2026.</li><li>Net product revenues: $208,000, up 106% YoY from $101,000.</li><li>Gross profit: $57,000; Operating expenses: $2.33 million.</li><li>Net loss: $2.40 million, or $0.90 per share, Q2 2026.</li><li>Going-concern risk; no manufacturing capacity.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term neutral-to-bearish; monitor cash runway and clinical progress over the next 6–12 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p>WASHINGTON, Aug.  14, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=na1CyiT5Cd8YbG4HMiTBjNXDYyRr1GzQllEJs6uZMHk4SzYVkEb_oIxqST2Ck3yVX43l4SyLCWptgWP3tFpaVGRtgRxRSIbZgPIB4-zDCvY9pKNIXsb1dM3qZ-HEGqTgyTa1WO3Rwgk0VSbR0xemqg==" rel="nofollow" target="_blank"><u>60 Degrees Pharmaceuticals, Inc.</u> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/SXTP">SXTP</a>, SXTPW)) (the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne diseases, reported today its financial results for the second quarter of 2026, ended June 30, 2026.</p>  <p><strong>Financial Highlights for the Quarter Ended June 30, 2026:</strong></p>  <ul type="disc"><li>Net product revenues increased approximately 106% to approximately $208 thousand for the second quarter of 2026, from approximately $101 thousand for the second quarter of 2025.</li><li>Gross profit on product revenues was approximately $57 thousand for the second quarter of 2026, compared with approximately $51 thousand for the second quarter of 2025.</li><li>Operating expenses were approximately $2.33 million for the second quarter of 2026, compared with approximately $1.86 million for the second quarter of 2025.</li><li>Net loss attributable to common stockholders was approximately $2.40 million, or $0.90 per share, for the second quarter of 2026, compared with a net loss of approximately $1.84 million, or $5.01 per share, for the second quarter of 2025.<br></br><br></br></li></ul>  <p style="padding-left:0pt;">Additional information regarding the Company&#39;s results is available in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.</p>  <p style="padding-left:0pt;"><strong>About 60 Degrees Pharmaceuticals, Inc.</strong></p>  <p style="padding-left:0pt;">60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA<sup>&#xAE;</sup> (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at <a href="https://www.globenewswire.com/Tracker?data=2bYVKrc_4y98ij-Rx9Pd1IVktG9B7TyjMOEwvM380KwAx0LeMCqxHwIOAKWyGhUZmmMmV7IOYsXNcDy9yj7HJnH0MV36D4yrX10T9nMZlug=" rel="nofollow" target="_blank"><u>www.60degreespharma.com</u></a>.</p>  <p style="padding-left:0pt;"><strong>Cautionary Note Regarding Forward-Looking Statements</strong><br></br>This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for <strong>tafenoquine</strong> (ARAKODA<sup>&#xAE;</sup> or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission ("SEC"), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>  <p>Media Contact:<br></br>Kristen Landon<br></br>kristenlandon@60degreespharma.com</p>  <p>Investor Contact:<br></br>Patrick Gaynes<br></br>patrickgaynes@60degreespharma.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTgxMDYwOCM3Nzc3NDMxIzIxODIzMzg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/OThiMTkwYjItY2E3YS00NzhhLTk2NDEtZTVkNTIwMGFlOTU3LTExOTM5MDctMjAyNi0wOC0xNC1lbg==/tiny/Sixty-Degrees-Pharmaceuticals.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c950cab5-27b1-476f-befc-4d92a7389fdd"><img src="https://ml.globenewswire.com/media/c950cab5-27b1-476f-befc-4d92a7389fdd/small/60degrees-logo-rgb-logo-jpg.jpg" border="0" width="150" height="79" alt="Primary Logo"></img></a></p>

60 Degrees reported Q2 2026 net product revenue of $208k, up 106% YoY, but net loss was $2.40M ($0.90 per share). Gross profit was $57k; operating expenses rose to $2.33M. The company cites going-concern risk and lack of manufacturing capacity, while pursuing babesiosis trials and ARAKODA sales for malaria prevention.

News insight

60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

AI summary

Sentiment rationale

Key facts

Earnings